Cholemic Nephropathy: Hyperbilirubinemia and its Impact on Renal Function

Main Article Content

Jonathan S Chávez-Iñiguez
Alejandra Meza-Ríos
Arturo Santos-Garcia
Guillermo García-García
Juan Armendáriz-Borunda


cholemic nephtropathy, extracorporeal albumin dialysis, hyperbilirubinemia, molecular adsorbent recirculating system, ursodeoxycholic acid


Cholemic nephropathy represents a spectrum of renal injury, from proximal tubulopathy to intrarenal bile cast formation, found in patients with severe liver dysfunction. It is caused by hyperbilirubinemia, usually in jaundiced patients. Acute kidney injury is one of the most important complications in patients with end-stage liver disease. The relationship between liver disease and renal impairment, especially the effect of hyperbilirubinemia on renal tissue and renal function, has not been fully elucidated. These considerations deem necessary for nephrologists, when performing a clinical evaluation of patients with liver diseases, for the implementation of an integrated medical approach. This review focuses on the current knowledge on cholemic nephropathy with emphasis on the role of hyperbilirubinemia on renal impairment. The treatment strategies and outcome are also discussed.


Download data is not yet available.
Abstract 1172 | PDF Downloads 1989 HTML Downloads 317 XML Downloads 340


1. Krones E, Pollheimer MJ, Rosenkranz AR, Fickert P. Cholemic nephropathy—Historical notes and novel perspectives. Biochim Biophys Acta Mol Basis Dis. 2018;1864(4 Pt B):1356–66.
2. Hecher R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure. Lancet 1956;2:1121–5.
3. Schroeder ET, Shear L, Sancetta SM, Gabuzda GJ. Renal failure in patients with cirrhosis of the liver. 3. Evaluation of intrarenal blood flow by para-aminohippurate extraction and response to angiotensin. Am J Med. 1967;43(6):887–96.
4. Aniort J, Poyet A, Kemeny JL, Philipponnet C, Heng AE. Bile cast nephropathy caused by obstructive cholestasis. Am J Kidney Dis. 2017;69(1):143–6.
5. Gonwa TA, Wadei HM. Kidney disease in the setting of liver failure: Core curriculum 2013. Am J Kidney Dis. 2013;62(6):1198–212.
6. Kalakonda, A. John, S. Physiology: Bilirubin. Treasure Island, FL: StatPearls Publishing; 2018.
7. Memon N, Weinberger BI, Hegyi T, Aleksunes LM. Inherited disorders of bilirubin Clearance. Pediatr Res. 2016;79(3):378–86.
8. Roche SP, Kobos R. Jaundice in the adult patient. Am Fam Physician. 2004;69(2):299–304.
9. Sticova E, Jirsa M. New insights in bilirubin metabolism and their clinical implications. World J Gastroenterol. 2013;19(38):6398–407.
10. Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol. 2008;48:S93–103.
11. Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis. Hepatology. 1994;20(6):1495–501.
12. Thabut D, Massard J, Gangloff A, Carbonell N, Francoz C, Nguyen-Khac E, et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology. 2007;46(6):1872–82.
13. Fasolato S, Angeli P, Dallagnese L, Maresio G, Zola E, Mazza E, et al. Renal failure and bacterial infections in patients with cirrhosis: Epidemiology and clinical features. Hepatology. 2007;45(1):223–9.
14. Montoliu S, Ballesté B, Planas R, Alvarez MA, Rivera M, Miquel M, et al. Incidence and prognosis of different types of functional renal failure in cirrhotic patients with ascites. Clin Gastroenterol Hepatol. 2010;8(7):616–22.
15. Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009;361:1279–90.
16. Martín-Llahí M, Guevara M, Torre A, Fagundes C, Restuccia T, Gilabert R, et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology 2011;140(2):488–96.
17. Angeli P, Ginès P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62(4):968–74.
18. Spencer K. Analytical reviews in clinical biochemistry: The estimation of creatinine. Ann Clin Biochem 1986;23(Pt. 1):1–25.
19. Watkins RE, Felkamp CS, Thibert RJ, Zak B. Interesting interferences in a direct serum creatinine reaction. Microchem J. 1976;21(4):370–84.
20. Poge U, Gerhardt T, Stoffel-Wagner B, Klehr HU, Sauerbruch T, Woitas RP. Calculation of glomerular filtration rate based on cystatin C in cirrhotic patients. Nephrol Dial Transplant. 2006;21(3):660–4.
21. van Slambrouck CM, Salem F, Meehan SM, Chang A. Bile cast nephropathy is a common pathologic finding for kidney injury associated with severe liver dysfunction. Kidney Int. 2013;84(1):192–7.
22. Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL et al. Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Supplements. 2012;1;2(1):1–138.
23. Fede G, D’Amico G, Arvaniti V, Tsochatzis E, Germani G, Georgiadis D, et al. Renal failure and cirrhosis: A systematic review of mortality and prognosis. J Hepatol. 2012;56(4):810–18.
24. Fagundes C, Barreto R, Guevara M, Garcia E, Solà E, Rodríguez E, et al. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepatol. 2013;59(3):474–81.
25. Sens F, Bacchetta J, Rabeyrin M, Julliard L. Efficacy of extracorporeal albumin dialysis for acute kidney injury due to cholestatic jaundice nephrotoxicity. BMJ Case Rep. 2016;2016:1–5.
26. Sitprija V, Kashemsant U, Sriratanaban A, Arthachinta S, Poshyachinda V. Renal function in obstructive jaundice in man: Cholangiocarcinoma mode. Kidney Int. 1990;38(5):948–55.
27. Mohapatra MK, Behera AK, Karua PC, Bariha PK, Rath A, Aggrawal KC, et al. Urinary bile casts in bile cast nephropathy secondary to severe falciparum malaria. Clin Kidney J. 2016;9(4):644–8.
28. Betjes M, Bajema I. The pathology of jaundice-related renal insufficiency: Cholemic nephrosis revisited. J Nephrol. 2006;19(2):229–33.
29. Martínez-Cecilia. D, Reyes-Díaz M, Ruiz-Rabelo J, Gomez-Alvarez M, Villanueva CM, Álamo J, et al. Oxidative stress influence on renal dysfunction in patients with obstructive jaundice: A case and control prospective study. Redox Biol. 2016;8:160–4.
30. Fickert P, Krones E, Pollheimer MJ, Thueringer A, Moustafa T, Silbert D, et al. Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice. Hepatology. 2013;58(6):2056–69.
31. Odell GB, Bolen JL, Poland RL, Seungdambong S, Cukier JO. Protection from bilirubin nephropathy in jaundiced Gunn rats. Gastroenterology. 1974;66(6):1218–24.
32. Bairaktari E, Liamis G, Tsolas O, Elisaf M. Partially reversible renal tubular damage in patients with obstructive jaundice. Hepatology. 2001;33(6):1365–9.
33. Holmes TW Jr. The histologic lesion of cholemic nephrosis. J Urol. 1953;70(5):677–85.
34. Jain K, Gupta A, Singh HK, Nickeleit V, Kshirsagar AV. Bile cast nephropathy. Kidney Int. 2015;87(2):484.
35. Elsom KA. Renal function in obstructive jaundice. Arch Intern Med (Chic). 1937;60 (6):1028–33.
36. Thompson LL, Frazier WD, Ravdin LS. The renal lesion in obstructive jaundice. Am J Med Sci. 1940;199:305–12.
37. Licata A, Maida M, Bonaccorso A, Macaluso FS, Cappello M, Craxì A, et al. Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study. World J Hepatol. 2013;27;5(12):685–91.
38. Nazar A, Pereira GH, Guevara M, Martín-Llahi M, Pepin MN, Marinelli M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2010;51(1):219–26.
39. de Vries E, Beuers U. Management of cholestatic disease in 2017. Liver Int. 2017;37(Suppl. 1):123–9.
40. Moustafa T, Fickert P, Magnes C, Guelly C, Thueringer A, Frank S, et al. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Gastroenterology. 2012;142(1):140–51.
41. Krones E, Eller K, Pollheimer MJ, Racedo S, Kirsch AH, Frauscher B, et al. Nor Ursodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice. J Hepatol. 2017;67(1):110–19.

Most read articles by the same author(s)